Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.30 ◽

2019 ◽

Vol 3 ◽

pp. S30

Author(s):

Brad Glick ◽

Edward Lain ◽

Tina Lin ◽

Robert Israel

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Oral Treatment ◽

Indirect Comparison ◽

Phase 3

Abstract not available.

Download Full-text

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.03.040 ◽

2018 ◽

Vol 79 (2) ◽

pp. 287-293 ◽

Cited By ~ 15

Author(s):

Linda Stein Gold ◽

Mark G. Lebwohl ◽

Jeffrey L. Sugarman ◽

David M. Pariser ◽

Tina Lin ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Plaque Psoriasis ◽

Fixed Combination ◽

Controlled Trials ◽

Phase 3 ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis ◽

Randomized Controlled

Download Full-text

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17113 ◽

2021 ◽

Author(s):

M.G. Lebwohl ◽

L. Stein Gold ◽

K. Papp ◽

G. Han ◽

D.M. Pariser ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.29 ◽

2019 ◽

Vol 3 ◽

pp. S29

Author(s):

Mark G Lebwohl ◽

Jeffrey L Sugarman ◽

Linda Stein Gold ◽

Tina Lin ◽

Gina Martin

Keyword(s):

Randomized Controlled Trials ◽

Plaque Psoriasis ◽

Fixed Combination ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Severe Plaque Psoriasis ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Post Hoc

Abstract not available.

Download Full-text

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.28 ◽

2019 ◽

Vol 3 ◽

pp. S28

Author(s):

Andrew F Alexis ◽

Paul S Yamauchi ◽

Tina Lin ◽

Gina Martin

Keyword(s):

Randomized Controlled Trials ◽

Plaque Psoriasis ◽

Fixed Combination ◽

Controlled Trials ◽

Hispanic Population ◽

Phase 3 ◽

Two Phase ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Post Hoc

Abstract not available.

Download Full-text

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.09.002 ◽

2019 ◽

Vol 80 (1) ◽

pp. 282-285 ◽

Cited By ~ 8

Author(s):

Mark G. Lebwohl ◽

Jeffrey L. Sugarman ◽

Linda Stein Gold ◽

David M. Pariser ◽

Tina Lin ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis

Download Full-text

Faculty Opinions recommendation of Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725715735.793510300 ◽

2015 ◽

Author(s):

Dafna Gladman ◽

Vinod Chandran

Keyword(s):

Psoriatic Arthritis ◽

Physical Function ◽

Plaque Psoriasis ◽

Phase 3

Download Full-text

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)

The Journal of Dermatology ◽

10.1111/1346-8138.15789 ◽

2021 ◽

Author(s):

Atsuyuki Igarashi ◽

Hidemi Nakagawa ◽

Akimichi Morita ◽

Yukari Okubo ◽

Shigetoshi Sano ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis

Download Full-text

Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17109 ◽

2021 ◽

Author(s):

D Thaçi ◽

AM Soliman ◽

K Eyerich ◽

A Pinter ◽

M Sebastian ◽

...

Keyword(s):

Clinical Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Patient Reported ◽

Acid Esters

Download Full-text

15190 Whole blood transcriptomic profiling in a phase 3 study of the efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.213 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB31

Author(s):

Shaojun Tang ◽

Arnaud Amzallag ◽

Robert Yang ◽

Peter H. Schafer

Keyword(s):

Plaque Psoriasis ◽

Whole Blood ◽

Efficacy And Safety ◽

Phase 3 ◽

Transcriptomic Profiling ◽

Severe Plaque Psoriasis

Download Full-text

Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants

Journal of Drugs in Dermatology ◽

10.36849/jdd.5698 ◽

2021 ◽

Vol 20 (3) ◽

pp. 252-258

Author(s):

Seemal Desai ◽

Brad Glick ◽

James Del Rosso ◽

Susan Harris ◽

Abby Jacobson

Keyword(s):

Plaque Psoriasis ◽

Phase 3 ◽

Once Daily ◽

Severe Plaque Psoriasis

Download Full-text